Volume 25, Number 4—April 2019
Research
Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia
Table 4
Specimens and MERS–CoV patients with detectable Abs, by time since illness onset and outcome, Saudi Arabia, August 1, 2015–August 31, 2016*
Outcome | Days since onset | No. specimens with Abs detected/no. tested |
No. patients† with Abs detected/no. tested |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
MN | VSV-MERS-S | S ELISA | N ELISA | MN | VSV-MERS-S | S ELISA | N ELISA | |||
Survived | <14 | 3/17 | 4/16 | 5/17 | 7/17 | 3/11 | 4/10 | 4/11 | 5/11 | |
14–20 | 4/8 | 4/8 | 4/8 | 6/8 | 3/5 | 3/5 | 3/5 | 4/5 | ||
21–27 | 6/6 | 5/5 | 6/6 | 6/6 | 3/3 | 3/3 | 3/3 | 3/3 | ||
28–55 | 10/10 | 10/10 | 10/10 | 10/10 | 4/4 | 4/4 | 4/4 | 4/4 | ||
1 y |
4/4 |
4/4 |
4/4 |
2/4 |
4/4 |
4/4 |
4/4 |
2/4 |
||
Died | <14 | 9/11 | 8/11 | 5/11 | 8/11 | 5/6 | 5/6 | 3/6 | 4/6 | |
14–20 | 9/9 | 6/8 | 7/9 | 9/9 | 4/4 | 2/3 | 4/4 | 4/4 | ||
21–27 | 9/9 | 8/9 | 8/9 | 9/9 | 4/4 | 4/4 | 4/4 | 4/4 | ||
28–55 | 4/4 | 4/4 | 4/4 | 4/4 | 3/3 | 3/3 | 3/3 | 3/3 | ||
1 y | NA | NA | NA | NA | NA | NA | NA | NA |
*Abs, antibodies; MERS-CoV, Middle East respiratory syndrome coronavirus; MN, microneutralization assay; N ELISA, nucleocapsid ELISA; S ELISA, spike ELISA; VSV-MERS-S, pseudoparticle neutralization assay; NA, not available.
†Number of patients represents those with available specimens for a given period. Specimens were not available from all patients during all periods. Some specimens were not tested by VSV-MERS-S pseudoparticle assay because of insufficient volume.
1These first authors contributed equally to this article.